EUCTR2009-012808-11-DE进行中(未招募)不适用
An open label, single dose, pharmacokinetic study of oromucosal midazolam administered to children from 3 months to less than 18 years undergoing routine elective surgery - Midazolam PK
Therakind Limited0 个研究点目标入组 75 人开始时间: 2009年8月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female aged from 3 months – <18years of age.
- •2. Attending the hospital for routine elective surgery
- •3. In the clinical opinion of the clinician in charge, the child requires midazolam for pre-medication treatment.
- •4. Parent(s) or legal guardian in attendance.
- •5. Parent(s)/legal guardian able and willing to provide written informed consent for the child to take part in the study.
- •6. Where applicable, the child should assent to undergo blood sampling for pharmacokinetic purposes and to allow physiological measurements to be made.
- •7. American Society of Anesthesiologists (ASA) classification of illness score of 2 or less
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Known allergy to benzodiazepine medications.
- •2. Exposure to benzodiazepines (including midazolam) in the preceding 7 days.
- •3. Exposure to drugs known to pharmacokinetically interact with midazolam in the preceding 7 days.
- •4. Receiving any chronic medication, except inhaled asthma therapies. Patients that have received periodic simple analgesics such as paracetamol, ibuprofen etc will not be excluded.
- •5. Participation in this or any clinical study in the previous 30 days or scheduled to receive any other investigational drug during the course of the study.
- •6. Any clinically significant medical condition or abnormality, which, in the opinion of the investigator, might compromise the safety of the patient or which might interfere with the study.
- •7. Females who are pregnant, lactating or planning to become pregnant.
- •8. Patients with a known history of epilepsy
研究者
相似试验
已完成
不适用
Bio availability study of Mangiferin from polyherbal formulatioCTRI/2014/01/004271SRM University10
进行中(未招募)
不适用
A single dose study of BeneFIX (nonacog alfa, recombinant factor IX) in male Chinese subjects with haemophilia B.EUCTR2015-003027-61-Outside-EU/EEAPfizer Inc.12
尚未招募
不适用
Bio availability study of Berberine in Manasamitra Vatakam: An ayurvedic herbomineral formulatioCTRI/2020/02/023267SRM Institute of Science and Technology
进行中(未招募)
不适用
Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia AHemophilia AEUCTR2015-003685-88-Outside-EU/EEAPfizer Inc.13
已完成
1 期
A study to investigate the safety, tolerability and activity of IPP-201101 in healthy volunteersSystemic lupus erythematosus (SLE)Musculoskeletal DiseasesSystemic lupus erythematosusISRCTN16878305ImmuPharma S.A16
